Doxycycline Macure: Uses, Dosage & Side Effects
A tetracycline antibiotic administered intravenously for the treatment of serious bacterial infections when oral therapy is not possible
Doxycycline Macure is an intravenous formulation of doxycycline, a broad-spectrum tetracycline antibiotic listed on the WHO Model List of Essential Medicines. This injectable preparation (20 mg/ml solution) is designed for use in hospitalized patients who require parenteral antibiotic therapy because they are unable to take oral medications. Doxycycline works by inhibiting bacterial protein synthesis at the ribosomal level and is effective against a wide range of gram-positive and gram-negative bacteria, atypical pathogens, and certain protozoa. It is commonly used for severe respiratory tract infections, pelvic inflammatory disease, rickettsial diseases, severe acne, and as part of combination regimens for malaria and anthrax.
Quick Facts: Doxycycline Macure
Key Takeaways
- Doxycycline Macure is an intravenous formulation (20 mg/ml) of the tetracycline antibiotic doxycycline, used when oral administration is not possible due to the patient's clinical condition.
- It is effective against a broad spectrum of bacteria including gram-positive and gram-negative organisms, atypical pathogens (Chlamydia, Mycoplasma, Rickettsia), spirochetes, and certain protozoa such as malaria parasites.
- The standard adult dosage is 200 mg on the first day followed by 100–200 mg daily, administered as a slow IV infusion over 1–4 hours to minimize the risk of thrombophlebitis.
- Key precautions include photosensitivity, avoidance in pregnancy (second/third trimester) and children under 8 years (except for life-threatening conditions), and numerous drug interactions including antacids, oral anticoagulants, and retinoids.
- Doxycycline is on the WHO Model List of Essential Medicines and has a long elimination half-life (18–22 hours), allowing convenient once or twice daily dosing with a smooth transition from IV to oral therapy when the patient improves.
What Is Doxycycline Macure and What Is It Used For?
Doxycycline Macure contains the active substance doxycycline, a semi-synthetic tetracycline antibiotic derived from oxytetracycline. Doxycycline was first synthesized in the early 1960s and has since become one of the most widely prescribed antibiotics worldwide. It is included on the World Health Organization (WHO) Model List of Essential Medicines, underscoring its importance in global healthcare. The Macure formulation is specifically designed for intravenous administration, providing a concentration of 20 mg/ml in solution form, intended for dilution and slow infusion in a clinical setting.
The mechanism of action of doxycycline involves reversible binding to the bacterial 30S ribosomal subunit. By occupying the aminoacyl-tRNA acceptor (A) site on the ribosome, doxycycline prevents the attachment of aminoacyl-tRNA molecules, thereby blocking the addition of amino acids to the nascent polypeptide chain. This results in the inhibition of bacterial protein synthesis. At therapeutic concentrations, doxycycline is primarily bacteriostatic, meaning it inhibits bacterial growth and replication rather than directly killing bacteria. The immune system then clears the infection. However, at higher concentrations, doxycycline may exhibit bactericidal activity against particularly susceptible organisms.
Beyond its antimicrobial properties, doxycycline possesses significant anti-inflammatory and immunomodulatory effects. It inhibits matrix metalloproteinases (MMPs), which are enzymes involved in tissue remodeling and destruction. This property has led to the use of sub-antimicrobial doses of doxycycline for conditions such as periodontal disease and rosacea. Doxycycline also modulates pro-inflammatory cytokine production, inhibits angiogenesis, and has demonstrated neuroprotective effects in preclinical studies. These pleiotropic properties distinguish doxycycline from many other antibiotics and have fueled ongoing research into its potential therapeutic applications beyond infection.
Doxycycline Macure is indicated for the treatment of a wide range of infections caused by susceptible organisms. The intravenous formulation is specifically reserved for situations where oral therapy is not feasible or appropriate. Common clinical indications include:
- Respiratory tract infections: Community-acquired pneumonia (particularly when atypical pathogens such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella pneumophila are suspected), acute exacerbations of chronic bronchitis, and sinusitis.
- Sexually transmitted infections: Chlamydial urethritis, non-gonococcal urethritis, pelvic inflammatory disease (PID, as part of combination therapy), lymphogranuloma venereum, and granuloma inguinale.
- Rickettsial infections: Rocky Mountain spotted fever (RMSF), Mediterranean spotted fever, Q fever, epidemic and murine typhus, and scrub typhus. Doxycycline is the treatment of choice for all rickettsial infections according to CDC and IDSA guidelines.
- Tick-borne infections: Lyme disease (Borrelia burgdorferi), ehrlichiosis, anaplasmosis, and relapsing fever.
- Severe skin and soft tissue infections: Including severe acne vulgaris, certain wound infections, and bite wound infections (animal and human).
- Anthrax: Post-exposure prophylaxis and treatment of all forms of anthrax (cutaneous, inhalational, gastrointestinal), as recommended by the CDC.
- Malaria: Prophylaxis and as part of combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria, particularly in areas with chloroquine resistance.
- Other infections: Brucellosis (in combination with streptomycin or gentamicin), cholera, plague (Yersinia pestis), tularemia, and certain ophthalmic infections.
The intravenous route is specifically chosen when patients are critically ill, experiencing persistent vomiting, are nil by mouth (NPO) for surgical or other medical reasons, or have gastrointestinal conditions that significantly impair oral absorption. Once the patient's clinical condition improves and oral intake becomes possible, clinicians typically perform an IV-to-oral switch (step-down therapy). This approach is supported by the excellent oral bioavailability of doxycycline, which approaches 95%, meaning that blood levels achieved with oral dosing are nearly equivalent to those achieved intravenously.
The IV formulation of doxycycline is not inherently more effective than oral doxycycline for susceptible infections. Its primary advantage is that it allows antibiotic therapy to begin immediately in patients who cannot swallow, are unconscious, or have severe gastrointestinal dysfunction. The pharmacokinetic profile is essentially identical to oral dosing once steady state is reached, supporting seamless IV-to-oral step-down when clinically appropriate.
What Should You Know Before Taking Doxycycline Macure?
Contraindications
Doxycycline Macure is contraindicated in patients with a known hypersensitivity to doxycycline, any other tetracycline antibiotic, or any of the excipients in the formulation. Tetracycline hypersensitivity can manifest as urticaria, angioedema, anaphylaxis, or severe skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), though these severe reactions are rare. Cross-sensitivity between different tetracycline antibiotics (tetracycline, minocycline, tigecycline) is possible but not absolute; patients with a history of reaction to one tetracycline should be carefully evaluated before receiving another.
Doxycycline is also contraindicated during the second and third trimesters of pregnancy due to the risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the developing fetus. Tetracyclines form stable calcium-orthophosphate complexes in bone-forming tissue, which can also impair fetal skeletal development. For similar reasons, doxycycline should not be used during breastfeeding, as it is excreted in breast milk and may affect the nursing infant's developing teeth and bones.
In children under 8 years of age, doxycycline has traditionally been contraindicated due to the risk of permanent dental staining. However, current evidence suggests that short courses of doxycycline (up to 21 days) in young children pose a minimal risk of clinically significant dental effects. The American Academy of Pediatrics (AAP) and the CDC now recommend doxycycline as the treatment of choice for suspected rickettsial infections (e.g., Rocky Mountain spotted fever) in children of all ages, as the risk of untreated rickettsial disease far outweighs the potential risk of dental discoloration from a short therapeutic course.
Warnings and Precautions
Photosensitivity: Doxycycline is well known for causing photosensitivity reactions, which can range from an exaggerated sunburn response to phototoxic dermatitis. Patients receiving doxycycline should be advised to avoid prolonged exposure to direct sunlight and ultraviolet (UV) light, including tanning beds. Protective clothing, broad-spectrum sunscreen (SPF 30+), and sun-avoidance strategies should be recommended. Photosensitivity can occur even on cloudy days and can persist for several days after discontinuation of the drug. The risk is dose-dependent and is more common at higher doses.
Clostridioides difficile-associated diarrhea (CDAD): As with all antibiotics, doxycycline can disrupt the normal intestinal flora, potentially leading to overgrowth of Clostridioides difficile and associated pseudomembranous colitis. However, doxycycline carries one of the lowest risks of CDAD among all antibiotics, and some observational data suggest it may even be protective. Nonetheless, patients who develop severe or persistent diarrhea during or after treatment should be evaluated for CDAD.
Hepatotoxicity: Doxycycline should be used with caution in patients with pre-existing hepatic impairment, as tetracyclines can cause hepatotoxicity, particularly when administered intravenously at high doses. Fatty liver changes and hepatocellular damage have been reported, though this is more commonly associated with older tetracyclines (particularly tetracycline itself) than with doxycycline. Patients with severe liver disease may require dose adjustment or alternative therapy.
Intracranial hypertension (pseudotumor cerebri): Doxycycline has been associated with benign intracranial hypertension (pseudotumor cerebri), particularly in women of childbearing age and in adolescents. Symptoms include headache, blurred vision, diplopia, and papilledema. This condition is usually reversible upon discontinuation of the drug but can cause permanent visual impairment if not recognized and treated promptly. The risk is increased when doxycycline is combined with retinoids such as isotretinoin (Accutane), and this combination should be avoided.
Infusion-related reactions: Because this is an intravenous formulation, Doxycycline Macure must be administered as a slow infusion, typically over 1 to 4 hours depending on the dose. Rapid intravenous injection can cause severe venous irritation, thrombophlebitis, and pain at the injection site. The solution must be properly diluted before administration, and the infusion site should be monitored for signs of extravasation or local tissue damage.
Never administer Doxycycline Macure as a rapid intravenous bolus. Always dilute the solution and infuse slowly over 1–4 hours. Rapid injection can cause severe thrombophlebitis, venous irritation, and potentially serious cardiovascular effects. Ensure adequate venous access and monitor the infusion site throughout administration.
Pregnancy and Breastfeeding
Doxycycline is classified as a drug that should be avoided during pregnancy, particularly during the second and third trimesters. The tetracycline class of antibiotics crosses the placental barrier and can be incorporated into developing fetal teeth and bones. Dental effects include permanent yellow-gray-brown discoloration and enamel hypoplasia, while skeletal effects include a reversible decrease in fibular growth rate. First-trimester exposure data are more limited, but available epidemiological studies have not shown a consistent increase in the risk of major congenital malformations. Nevertheless, doxycycline should be used during the first trimester only when no suitable alternative exists and the potential benefit clearly justifies the potential risk to the fetus.
Doxycycline is excreted in human breast milk in measurable concentrations. While the absolute amount transferred to the nursing infant is small (estimated at less than 6% of the maternal dose), the potential for dental staining and effects on bone growth in the infant means that doxycycline should generally be avoided during breastfeeding. If treatment is absolutely necessary, temporary cessation of breastfeeding during therapy and for at least 24 hours after the last dose may be considered. Alternative antibiotics that are compatible with breastfeeding should be used when possible.
For pregnant women who require treatment for life-threatening rickettsial infections (such as Rocky Mountain spotted fever), doxycycline remains the drug of choice regardless of gestational age, as the risk of untreated disease (which can be fatal) far outweighs the potential risk of dental staining. This recommendation is supported by the CDC, the American College of Obstetricians and Gynecologists (ACOG), and the Infectious Diseases Society of America (IDSA).
How Does Doxycycline Macure Interact with Other Drugs?
Doxycycline has clinically significant interactions with a number of medications. Although the IV route bypasses some absorption-related interactions, these interactions become relevant during IV-to-oral step-down therapy and should be anticipated during treatment planning. Additionally, several interactions involve pharmacodynamic mechanisms that apply regardless of the route of administration.
Major Interactions
| Interacting Drug | Effect | Clinical Management |
|---|---|---|
| Retinoids (isotretinoin, acitretin) | Increased risk of intracranial hypertension (pseudotumor cerebri) | Combination is contraindicated. Do not use concurrently. |
| Oral anticoagulants (warfarin) | Potentiation of anticoagulant effect; increased INR and bleeding risk | Monitor INR frequently. Dose adjustment of warfarin may be required. |
| Methotrexate | Increased methotrexate toxicity due to reduced renal clearance | Monitor methotrexate levels and renal function closely. |
| Ciclosporin | Increased ciclosporin levels; nephrotoxicity risk | Monitor ciclosporin trough levels and renal function. |
| Penicillins and other bactericidal antibiotics | Theoretical antagonism: bacteriostatic doxycycline may reduce the efficacy of bactericidal agents | Avoid combination when possible. If co-administered, monitor clinical response closely. |
Minor Interactions
| Interacting Drug | Effect | Clinical Management |
|---|---|---|
| Antacids (Al, Ca, Mg) | Chelation reduces oral doxycycline absorption by up to 50% | Separate oral doxycycline from antacids by at least 2–3 hours. |
| Iron supplements | Chelation reduces oral doxycycline absorption | Separate administration by at least 2–3 hours. |
| Oral contraceptives | Potential reduction in contraceptive efficacy (debated) | Use additional barrier contraception during treatment and for 7 days after. |
| Phenytoin, carbamazepine, barbiturates | Enzyme inducers decrease doxycycline half-life by up to 50% | Consider higher doses or alternative antibiotic. Monitor clinical response. |
| Rifampicin | Significantly reduces doxycycline plasma concentrations | Avoid combination. Use alternative antibiotic if possible. |
It is important to note that many of the absorption-related interactions (antacids, iron, calcium) are relevant primarily when transitioning from IV to oral doxycycline. During IV therapy, these interactions do not apply because the drug bypasses the gastrointestinal tract. However, clinicians should anticipate these interactions and counsel patients appropriately before initiating oral step-down therapy. All current medications, including over-the-counter supplements and herbal products, should be reviewed at the time of prescribing to identify and manage potential interactions.
What Is the Correct Dosage of Doxycycline Macure?
Doxycycline Macure is administered exclusively by intravenous infusion. The solution must be diluted to an appropriate concentration before administration and infused slowly over a minimum of 1 hour (for 100 mg doses) to 4 hours (for 200 mg doses given as a single infusion). Rapid injection must be avoided due to the risk of venous irritation, thrombophlebitis, and cardiovascular complications. Compatible diluents include 0.9% sodium chloride (normal saline), 5% dextrose in water (D5W), Ringer's lactate solution, and other standard intravenous solutions as specified by the manufacturer.
Adults
Standard Adult Dosing
Day 1 (Loading dose): 200 mg IV, administered either as a single infusion or divided into two infusions of 100 mg each (separated by 12 hours).
Subsequent days: 100–200 mg IV once daily, depending on the severity and type of infection.
Duration: Varies by indication, typically 7–14 days for most infections. Some conditions (e.g., brucellosis) require longer courses of 6 weeks or more.
| Indication | Dose | Duration |
|---|---|---|
| Community-acquired pneumonia | 200 mg Day 1, then 100–200 mg/day | 7–14 days |
| Pelvic inflammatory disease | 100 mg IV every 12 hours (+ ceftriaxone) | 14 days total (IV then oral step-down) |
| Rocky Mountain spotted fever | 100 mg IV every 12 hours | At least 3 days after fever resolves (min. 5–7 days) |
| Anthrax (inhalational) | 100 mg IV every 12 hours (+ combination therapy) | 60 days total (IV then oral step-down) |
| Brucellosis | 100 mg IV every 12 hours (+ aminoglycoside) | 6 weeks |
| Malaria (treatment, combination) | 100 mg IV every 12 hours (+ quinine) | 7 days |
Children
Pediatric Dosing (Children Over 8 Years or for Life-Threatening Infections)
Children over 45 kg: Same as adult dosing.
Children under 45 kg (over 8 years): 4.4 mg/kg on Day 1 (divided into 1–2 infusions), followed by 2.2–4.4 mg/kg/day in 1–2 divided infusions.
Children under 8 years: Use only for life-threatening infections (e.g., Rocky Mountain spotted fever, anthrax) where no alternative exists. Dosing: 2.2 mg/kg IV every 12 hours.
Elderly
No specific dose adjustment is required for elderly patients based solely on age. However, elderly patients are more likely to have impaired hepatic function, reduced physiological reserve, and concurrent medications that interact with doxycycline. Careful assessment of hepatic function, renal function, and the patient's overall medication profile is advisable. The infusion rate should be conservative, and the patient should be monitored for signs of venous irritation or adverse effects. Elderly patients may also be at higher risk for esophageal irritation during the transition to oral therapy.
Missed Dose
In the hospital setting, doses of Doxycycline Macure are administered by healthcare professionals according to a prescribed schedule, so missed doses are uncommon. If a dose is inadvertently missed, it should be given as soon as the omission is recognized. If it is close to the time of the next scheduled dose, the missed dose may be skipped to avoid doubling up. The prescribing physician or pharmacist should be notified, and the dosing schedule should be adjusted accordingly. Maintaining consistent blood levels of doxycycline is important for optimal antimicrobial efficacy.
Overdose
Acute overdose of intravenous doxycycline is rare in clinical practice due to the controlled hospital setting. Symptoms of overdose may include severe nausea, vomiting, diarrhea, and dizziness. In extreme cases, hepatotoxicity and pancreatitis may occur. There is no specific antidote for doxycycline overdose. Treatment is supportive and symptomatic: discontinue the infusion immediately, provide intravenous fluids, monitor liver function and electrolytes, and manage symptoms as they arise. Hemodialysis is not effective in removing doxycycline from the body due to its high protein binding (80–95%). Activated charcoal may be considered if the patient has also ingested oral doxycycline, provided it can be given within 1–2 hours of ingestion.
Unlike older tetracyclines, doxycycline does not accumulate significantly in renal failure because it is primarily eliminated via the gastrointestinal tract rather than the kidneys. No dose adjustment is required for patients with renal impairment, including those on dialysis. However, caution is advised in patients with severe hepatic impairment, as doxycycline undergoes hepatic metabolism and may accumulate in liver disease. Liver function should be monitored in patients receiving prolonged courses.
What Are the Side Effects of Doxycycline Macure?
Like all medications, Doxycycline Macure can cause side effects, although not everyone will experience them. The following classification uses the standard frequency conventions defined by the Council for International Organizations of Medical Sciences (CIOMS): very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), and very rare (<1/10,000). The side effect profile of IV doxycycline is generally similar to that of oral doxycycline, with the addition of infusion site reactions that are specific to the intravenous route.
Very Common (≥1 in 10 patients)
These side effects occur in more than 10% of patients
- Nausea
- Photosensitivity (increased sensitivity to sunlight)
Common (1 in 10 to 1 in 100 patients)
These side effects occur in 1–10% of patients
- Vomiting
- Diarrhea
- Abdominal pain or discomfort
- Thrombophlebitis at infusion site
- Pain and redness at injection site
- Loss of appetite (anorexia)
- Oral or vaginal candidiasis (yeast infection)
- Skin rash
Uncommon (1 in 100 to 1 in 1,000 patients)
These side effects occur in 0.1–1% of patients
- Dysphagia (difficulty swallowing)
- Esophageal ulceration or irritation
- Glossitis (inflammation of the tongue)
- Headache
- Dizziness
- Blurred vision
- Elevated liver enzymes (transaminases)
- Urticaria (hives)
- Pruritus (itching)
Rare (less than 1 in 1,000 patients)
These side effects occur in fewer than 0.1% of patients
- Clostridioides difficile-associated diarrhea (pseudomembranous colitis)
- Intracranial hypertension (pseudotumor cerebri)
- Hepatotoxicity (liver damage)
- Pancreatitis
- Blood disorders (hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia)
- Anaphylaxis or severe allergic reaction
- Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Photoonycholysis (nail changes from sun exposure)
- Permanent tooth discoloration (in children under 8 years)
Patients should report any persistent, worsening, or unexpected symptoms to their healthcare provider promptly. In particular, severe diarrhea (especially if bloody or watery), signs of allergic reaction (rash, swelling, difficulty breathing), visual disturbances, or severe headache should be evaluated urgently. For photosensitivity, sun avoidance and protective measures should be maintained during treatment and for several days after completing therapy.
The infusion site reactions (thrombophlebitis, pain, redness) can be minimized by using a large-bore vein, diluting the solution adequately, and infusing slowly over the recommended time period. Rotating infusion sites and monitoring for early signs of phlebitis can help prevent more serious local complications. If significant thrombophlebitis develops, the infusion site should be changed and symptomatic treatment (warm compresses, elevation) should be applied.
If you experience any side effects, including those not listed above, please tell your doctor, pharmacist, or nurse. You can also report side effects directly to your national medicines regulatory authority (e.g., the FDA MedWatch program in the US, the Yellow Card Scheme in the UK, or the EMA EudraVigilance system in the EU). By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Doxycycline Macure?
Doxycycline Macure should be stored at controlled room temperature, not exceeding 25°C (77°F). The solution should be protected from direct light, as doxycycline is photosensitive and can degrade when exposed to ultraviolet or intense visible light. The original packaging provides light protection, and the product should be kept in its carton until the time of use. Do not freeze the product, as freezing may alter the physical and chemical properties of the solution.
Once the vial has been opened and the solution has been diluted for intravenous infusion, it should be used within the timeframe specified by the manufacturer and local pharmacy guidelines, typically within 12 to 24 hours when stored at room temperature, or up to 48 hours when refrigerated at 2–8°C (36–46°F). Diluted solutions should be inspected visually for particulate matter and discoloration prior to administration. If the solution appears cloudy, contains particles, or has changed color, it should not be used and must be discarded according to local disposal regulations for pharmaceutical waste.
As with all medications, Doxycycline Macure should be kept out of the sight and reach of children. Do not use this medicine after the expiry date printed on the carton and vial. The expiry date refers to the last day of that month. Do not dispose of medicines via wastewater or household waste; return unused products to a pharmacy for proper disposal in accordance with local environmental regulations.
What Does Doxycycline Macure Contain?
The active substance in Doxycycline Macure is doxycycline, present at a concentration of 20 mg per milliliter of solution. Doxycycline is a member of the tetracycline class of antibiotics, chemically designated as 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide. Its molecular formula is C22H24N2O8, and its molecular weight is approximately 444.4 g/mol. Doxycycline is a yellow to light-yellow crystalline powder that is sparingly soluble in water. In the Macure formulation, it is prepared as a sterile solution suitable for intravenous use after appropriate dilution.
The excipients (inactive ingredients) in the formulation are designed to maintain the stability, solubility, and appropriate pH of the solution for intravenous administration. Typical excipients in intravenous doxycycline formulations include water for injection as the primary solvent, and pH-adjusting agents such as hydrochloric acid or sodium hydroxide to maintain the solution within an acceptable pH range (typically pH 1.8–3.3). Some formulations may also contain propylene glycol or other co-solvents to enhance doxycycline solubility, as well as meglumine or other stabilizing agents.
Patients with known hypersensitivity to any of the excipients should inform their healthcare provider before receiving Doxycycline Macure. The complete list of excipients can be found in the patient information leaflet supplied with the product or by contacting the manufacturer directly. Each batch of Doxycycline Macure is manufactured under strict Good Manufacturing Practice (GMP) conditions and undergoes rigorous quality control testing before release.
Frequently Asked Questions About Doxycycline Macure
Doxycycline Macure is an intravenous formulation of doxycycline used to treat serious bacterial infections when oral therapy is not feasible. Common indications include severe pneumonia, pelvic inflammatory disease, rickettsial infections (such as Rocky Mountain spotted fever), anthrax (post-exposure prophylaxis and treatment), brucellosis, cholera, and certain sexually transmitted infections. It is also used for malaria prophylaxis and treatment in combination regimens.
Doxycycline Macure is administered as a slow intravenous infusion, typically over 1 to 4 hours depending on the dose and volume. The standard adult dose is 200 mg on the first day (given as a single infusion or divided into two 100 mg infusions), followed by 100–200 mg daily. The solution must be diluted before administration and should not be given as a rapid IV push due to the risk of thrombophlebitis and cardiovascular complications.
Doxycycline has traditionally been avoided in children under 8 years due to the risk of permanent tooth discoloration. However, recent evidence and guidelines from the American Academy of Pediatrics (AAP) now support short courses (up to 21 days) in children of all ages for serious conditions such as Rocky Mountain spotted fever, where the benefits clearly outweigh the risks. For children over 8 years, doxycycline can be used for the same range of indications as in adults.
Doxycycline Macure is an intravenous formulation designed for patients who cannot take oral medications. The IV route provides immediate and complete bioavailability, whereas oral doxycycline absorption can be affected by food and divalent cations. Since oral doxycycline has approximately 95% bioavailability, clinicians typically switch from IV to oral as soon as the patient can tolerate oral therapy (known as IV-to-oral step-down). The antimicrobial efficacy is equivalent between routes.
Unlike older tetracyclines, doxycycline does not accumulate in renal failure because it is primarily eliminated via the gastrointestinal tract rather than the kidneys. No dose adjustment is required for patients with renal impairment, including those undergoing hemodialysis. This makes doxycycline the preferred tetracycline for patients with chronic kidney disease. However, caution is warranted in patients with severe hepatic impairment, as doxycycline undergoes some hepatic metabolism.
Doxycycline Macure should not be used during the second and third trimesters of pregnancy due to the risk of permanent tooth discoloration and impaired bone development in the fetus. Use during the first trimester should be avoided unless no suitable alternative exists. For life-threatening infections such as Rocky Mountain spotted fever in pregnant women, doxycycline remains the drug of choice regardless of gestational age, as the risk of untreated disease outweighs the potential risks to the fetus.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023. Doxycycline is listed as an essential antibiotic for multiple indications.
- European Medicines Agency (EMA). Summary of Product Characteristics: Doxycycline solutions for injection. EMA; 2025. Comprehensive prescribing information for the European market.
- U.S. Food and Drug Administration (FDA). Doxycycline Hyclate Injection – Prescribing Information. FDA; 2024. Full US prescribing information including dosing, warnings, and interactions.
- Infectious Diseases Society of America (IDSA). Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections. Clinical Infectious Diseases. 2024;78(2):e51–e76.
- British National Formulary (BNF). Doxycycline Monograph. NICE; 2025. UK clinical guidance including dosing, interactions, and monitoring recommendations.
- Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr. 2015;166(5):1246–1251. doi:10.1016/j.jpeds.2015.02.015.
- Centers for Disease Control and Prevention (CDC). Diagnosis and Management of Tickborne Rickettsial Diseases. MMWR Recomm Rep. 2023;72(RR-5):1–44.
- Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood. Lancet Infect Dis. 2016;16(8):e164–e172. doi:10.1016/S1473-3099(16)30071-6.
- Holmes NE, Charles PG. Safety and efficacy review of doxycycline. Clin Med Insights Ther. 2018;1:1–10.
- Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2017;18(4):469–490. doi:10.1007/s40257-017-0267-z.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in infectious disease, clinical pharmacology, and antimicrobial therapy.
Medical Writer
iMedic Medical Editorial Team – Specialists in Infectious Disease and Pharmacology
Medical Reviewer
iMedic Medical Review Board – Board-certified physicians following international guidelines (WHO, EMA, FDA, IDSA, BNF)
Evidence Framework
GRADE methodology – Evidence Level 1A based on systematic reviews and clinical guidelines
Accessibility Review
WCAG 2.2 Level AAA compliance verified – Screen reader optimized, keyboard navigable, high contrast
All content is independently developed with no pharmaceutical company sponsorship or advertising. Our editorial standards require peer-reviewed references, adherence to international clinical guidelines, and regular content updates to reflect the latest evidence.